UCB SA (OTCMKTS:UCBJY) Sees Large Growth in Short Interest

UCB SA (OTCMKTS:UCBJY) was the recipient of a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 2,600 shares, an increase of 1,200.0% from the March 31st total of 200 shares. Based on an average daily volume of 24,200 shares, the short-interest ratio is currently 0.1 days.

UCB Stock Up 3.9 %

UCB stock traded up $2.51 during trading on Thursday, reaching $67.30. 31,930 shares of the company’s stock were exchanged, compared to its average volume of 12,260. The company’s 50-day moving average is $59.36 and its two-hundred day moving average is $47.89. UCB has a 52-week low of $34.85 and a 52-week high of $67.30.

UCB Cuts Dividend

The firm also recently declared a dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 29th will be given a dividend of $0.4574 per share. The ex-dividend date of this dividend is Friday, April 26th. This represents a yield of 0.71%. UCB’s dividend payout ratio (DPR) is 46.55%.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.